In vitro synergistic effects of zoledronic acid and calcium on viability of human epithelial cells

Oral Diseases

Volumn 19, Issue 2, 2013, Pages 200-205

  Arai, N ^a   Inoue, S ^a   Tomihara, K ^a   Tsuno, H ^a   Noguchi, M ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Bisphosphonate; Keratinocytes; Oral mucosa; Osteonecrosis; Serum; Zoledronate

Indexed keywords

CALCIUM; LIPOCORTIN 5; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CALCIUM BLOOD LEVEL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KERATINOCYTE; PRIORITY JOURNAL; REDUCTION; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; EPITHELIUM CELL; PHYSIOLOGY;

CALCIUM; CELL SURVIVAL; CELLS, CULTURED; DIPHOSPHONATES; DRUG SYNERGISM; EPITHELIAL CELLS; HUMANS; IMIDAZOLES;

EID: 84878162851     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2012.01971.x     Document Type: Article

References (32)

1. Abrahamsen B (2010). Adverse effects of bisphosphonate. Calcif Tissue Int 86: 421-435.
2. Agis H, Blei J, Watzek G, Gruber R (2010). Is zoledronate toxic to human periodontal fibroblasts? J Dent Res 89: 40-45.
3. Allam E, Allen M, Chu TM, Ghoneima A, Jack Windsor L (2011). In vivo effects of zoledronic acid on oral mucosal epithelial cells. Oral Dis 17: 291-297.
4. Chen T, Berenson J, Vescio R et al (2002). Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42: 1228-1236.
5. Clézardin P (2009). Insights into the antitumor effects of bisphosphonates from preclinical models and potential clinical implications. IBMS BoneKEy 6: 210-217.
6. Di Salvatore M, Orlandi A, Bagalà C et al (2011). Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 44: 139-146.
7. Dunford JE, Thompson K, Coxon FP et al (2001). Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242.
8. Fournier P, Boissier S, Filleur S et al (2002). Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544.
9. Hansen T, Kunkel M, Weber A, Kirkpatrick CJ (2006). Osteonecrosis of the jaws in the patients treated with bisphosphonates - histomorphological analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160.
10. Journé F, Kheddoumi N, Chaboteaux C, Duvillier H, Laurent G, Body JJ (2008). Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells. Breast Cancer Res, 10: R4, DOI:10.1186/bcr1845.
11. Kim RH, Lee RS, Williams D et al (2011). Bisphosphonates induce senescence in normal human oral keratinocytes. J Dent Res 90: 810-816.
12. Kyrgidis A, Triaridis ST, Vahtsevanos K (2009). New evidence on bisphosphonate related osteonecrosis of the jaws suggests dental referral prior to commencement of treatment. Hippokratia 13: 64.
13. Landesberg R, Cozin M, Cremers S et al (2008). Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66: 839-847.
14. Landesberg R, Woo V, Cremers S et al (2011). Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann NY Acad Sci 1218: 62-79.
15. Marx RE (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117.
16. Mönkkönen J, Taskinen M, Auriola SO, Urtti A (1994). Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. J Drug Target 2: 299-308.
17. Pabst AM, Ziebart T, Koch FP, Taylor KY, Al-Nawas B, Walter C (2011). The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes-in vitro study. Clin Oral Invest 16: 87-93. DOI: 10.1007/s00784-010-0507-6.
18. Reid IR (2009). Osteonecrosis of the jaw-who gets it, and why? Bone 44: 4-10.
19. Reid IR, Bolland MJ, Grey AB (2007). Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41: 318-320.
20. Reszka AA, Halasy-Nagy J, Rodan GA (2001). Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 50: 193-202.
21. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J (2011). Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49: 34-41.
22. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004). Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527-534.
23. Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF (2009). Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144: 667-676.
24. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW (2008). Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 66: 767-775.
25. Skerjanec A, Berenson J, Hsu C et al (2003). The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 43: 154-162.
26. Smith MR (2003). Antitumor activity of bisphosphonates. Clin Cancer Res 9: 5433-5434.
27. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009). Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45: 164-172.
28. Stanley JR, Yuspa SH (1983). Specific epidermal protein markers are modulated during calcium-induced terminal differentiation. J Cell Biol 96: 1809-1814.
29. Thompson K, Rogers MJ, Coxon FP, Crockett JC (2006). Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 69: 1624-1632.
30. Twiss IM, Pas O, Ramp-Koopmanschap W, Den Hartigh J, Vermeij P (1999). The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res 14: 784-791.
31. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L (2010). Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tisuue Int 86: 110-115.
32. Wessel JH, Dodson TB, Zavras AI (2008). Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66: 625-631.